Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2

Brandi N. Williamson a, Lizzette Pérez-Pérez a, Benjamin Schwarz b, Friederike Feldmann c, Myndi G. Holbrook a, Manmeet Singh a, Diane S. Lye d, Darius Babusis d, Raju Subramanian d, Elaine Haddock a, Atsushi Okumura a, Patrick W. Hanley b, Jamie Lovaglio c, Catharine M. Bosio b, Danielle P. Porter d, Tomas Cihlar d, Richard L. Mackman d, Greg Saturday c, Emmie de Wit a, b, c, d

Article info

Keywords:
COVID-19
Antiviral
Animal model

Abstract

The utility of remdesivir treatment in COVID-19 patients is currently limited by the necessity to administer this antiviral intravenously, which has generally limited its use to hospitalized patients. Here, we tested a novel, subcutaneous formulation of remdesivir in the rhesus macaque model of SARS-CoV-2 infection that was previously used to establish the efficacy of remdesivir against this virus in vivo. Compared to vehicle-treated animals, macaques treated with subcutaneous remdesivir from 12 h through 6 days post inoculation showed reduced signs of respiratory disease, a reduction of virus replication in the lower respiratory tract, and an absence of interstitial pneumonia. Thus, early subcutaneous administration of remdesivir can protect from lower respiratory tract disease caused by SARS-CoV-2.

The nucleotide prodrug remdesivir was shown to be effective against SARS-CoV-2 in rhesus macaques early after the emergence of this virus (Williamson et al., 2020). The first clinical trial data indicated a shorter time to recovery in hospitalized COVID-19 patients treated with remdesivir (Beigel et al., 2020). However, mixed results were obtained in subsequent clinical trials assessing the efficacy of remdesivir in COVID-19 patients (reviewed in Aleissa et al., 2020). The use of remdesivir as a treatment for COVID-19 has largely been limited to hospitalized patients whose disease has already progressed due to the fact that the current formulation of remdesivir has to be administered intravenously on 5 consecutive days. However, it was shown early on that this treatment earlier during infection when virus replication peaks, would likely result in a greater treatment efficacy (Beigel et al., 2020). Indeed, an 87% reduction in hospitalization in non-hospitalized, high-risk COVID-19 patients was recently observed in a randomized, placebo-controlled clinical trial assessing outpatient treatment with a 3-day course of remdesivir (Gottlieb et al., 2021). Alternate routes of administration such as subcutaneous injection may enable earlier treatment prior to hospitalization which could maximize the therapeutic benefit of remdesivir.

A comparison of the pharmacokinetics of the subcutaneous remdesivir formulation to the previously used intravenous formulation was performed in healthy, uninfected Indian-origin rhesus macaques. Levels of remdesivir and its main metabolites were measured by LC-MS/MS in plasma and lung tissue as previously described (Cox et al., 2021). As expected, somewhat different pharmacokinetic profiles for remdesivir and its metabolites were observed following subcutaneous administration (Table S1 and Fig. S1). Compared to intravenous administration, 30-fold and 8-fold lower maximal concentrations (C max ), with more persistent levels, were observed for remdesivir (GS-5734) and its alanine metabolite GS-704277, respectively (Table S1). Additionally, the nucleoside metabolite GS-441524 appeared more slowly in plasma and persisted with a longer estimated terminal elimination half-life following subcutaneous dosing. Daily exposures (AUC 0-24h) were

* Corresponding author.
E-mail address: emmie.dewit@nih.gov (E. de Wit).

https://doi.org/10.1016/j.antiviral.2022.105246
Received 2 November 2021; Received in revised form 30 December 2021; Accepted 10 January 2022
Available online 13 January 2022
0166-3542/© 2022 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND IGO license

https://creativecommons.org/licenses/by-nc-nd/3.0/igo/
lower for remdesivir and greater for the alanine metabolite, indicative of a slower release of remdesivir from the injection site. Importantly, the active triphosphate (TP) metabolite levels in lungs at 24 h following either route of administration were not substantially different (Table S1). Therefore, we tested the efficacy of the subcutaneous formulation of remdesivir in the rhesus macaque model of SARS-CoV-2 infection (Munster et al., 2020).

Animal efficacy experiments were approved by the Institutional Animal Care and Use Committee of Rocky Mountain Laboratories, NIH and carried out in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International accredited facility, according to the institution’s guidelines for animal use, following the guidelines and basic principles in the Guide for the Care and Use of Laboratory Animals, the Animal Welfare Act, United States Department of Agriculture and the United States Public Health Service Policy on Humane Care and Use of Laboratory Animals. The Institutional Biosafety Committee (IBC) approved work with infectious SARS-CoV-2 strains under BSL3 conditions. Sample inactivation was performed according to IBC-approved standard operating procedures for removal of specimens from high containment.

Twelve Indian-origin rhesus macaques (11 females and 1 male; 4–7 years old) were randomly assigned to two groups of 6 animals. All animals were inoculated with a total dose of $2.6 \times 10^6$ TCID50 of SARS-CoV-2 strain nCoV-WA1-2020 (Vero E6 passage 4; no SNPs were detected in the inoculum at $>5\%$ by NGS) via intranasal (1 ml), oral (1 ml), ocular (0.5 ml) and intratracheal (4 ml) routes, as was done in our previous study assessing the efficacy of intravenous remdesivir administration (Williamson et al., 2020). At 12 h post inoculation (hpi), one group received a 10 mg/kg remdesivir loading dose via subcutaneous injection divided over two sites. Remdesivir solution was provided by Gilead Sciences as 50 mg/ml remdesivir in parenteral grade N-methyl-2-pyrrolidone (NMP). The second group of animals received an equivalent volume of NMP vehicle alone. At 24 hpi and every 24 h thereafter through 6 days post inoculation (dpi), treatment was continued with 5 mg/kg remdesivir or the equivalent volume of vehicle via a single subcutaneous injection. On 7 dpi, all animals were euthanized and skin was collected from the site of the last subcutaneous treatment. Injection site lesions were observed after subcutaneous injections with remdesivir and vehicle. Injection site lesions were generally more severe in remdesivir-treated animals; 5 out of 6
remdesivir-treated animals had mild to marked neutrophilic panniculitis and myositis with occasional myocyte necrosis, while 3 out of 6 vehicle-treated animals had minimal to mild panniculitis and myositis (Fig. S2). Phase I studies in humans would have to be performed to assess the severity of injection site lesions and whether their severity precludes use of subcutaneous administration of remdesivir.

Remdesivir and remdesivir metabolite levels were measured in the SARS-CoV-2-infected animals by LC-MS in plasma collected on 1, 3, 5 dpi just prior to the next treatment administration, as well as at the end of the experiment on 7 dpi, representing the circulating minimum concentrations throughout the dosage regimen. Intact remdesivir (GS-5734), alanine metabolite (GS-704277), and nucleoside metabolite (GS-441524) were readily detectable at all timepoints post-administration at levels similar to previous plasma measurements following intravenous remdesivir administration (Fig. S3A) (Warren et al., 2016). Plasma levels displayed higher concentrations of the GS-5734 prodrug compared to previous serum measurements made after intravenous remdesivir administration. At necropsy on 7 dpi, remdesivir and its metabolites were measured in lung tissue samples. Consistent with previous measurements made in a bioc containment setting (Williamson et al., 2020), only GS-441524 was detectable in lung samples since the sample analysis methodology employed in the biocContainment settings enables the detection and quantification of the nucleoside metabolite GS-441524, but does not allow for the detection of the intact active TP metabolite. GS-441524 was detected in all lung sections from all remdesivir-treated animals but the measured levels were in the lower range of values previously observed following intravenous administration (Fig. S3B). These data indicate that remdesivir was distributed to the lungs upon subcutaneous administration but accumulated to levels equivalent to or lower than those reached after intravenous administration, consistent with the pharmacokinetic analysis in healthy uninfected animals (Fig. S1).

After inoculation with SARS-CoV-2, the animals were scored daily for the presence of clinical signs according to a standardized scoring sheet (Munster et al., 2020) by a person blinded to the group assignment of the animals. Upon inoculation with SARS-CoV-2, the animals developed only mild signs of disease and no obvious differences in overall clinical scores were detected between the two groups (Fig. 1A). However, throughout the study, only 2 of 6 animals in the remdesivir-treated group developed respiratory disease signs (i.e. tachypnea and dyspnea), whereas all animals in the vehicle-treated group displayed respiratory signs (Fig. 1B). This correlated well with the presence of pulmonary infiltrates detected on radiographs, with 5/6 vehicle-treated animals having pulmonary infiltrates versus 2 remdesivir-treated animals (Fig. 1C). Thus, although the overall clinical scores were mainly determined by a lack of appetite observed in all animals that may have been affected by daily anesthesia required for drug administration, the treatment with subcutaneous remdesivir resulted in a reduction in respiratory disease. To monitor virus replication in the respiratory tract, nose and throat swabs were collected daily after inoculation and analyzed for the presence of SARS-CoV-2 genomic RNA (gRNA), as well as subgenomic RNA (sgRNA) as an indicator of recent virus replication. As with intravenous remdesivir treatment (Williamson et al., 2020), virus shedding from the upper respiratory tract was not affected by remdesivir treatment (Fig. S4). Subcutaneous remdesivir treatment reduced virus replication in the lower respiratory tract; on 3 and 7 dpi, significantly lower levels of sgRNA and gRNA, respectively, were detected in bronchoalveolar lavage (BAL) fluid of remdesivir-treated animals than that of vehicle controls (Fig. 1D). Additionally, there was a >100-fold reduction in virus titer in BAL fluid collected 12 h after the
first treatment administration, as was previously observed with intravenous remdesivir treatment (Williamson et al., 2020). On 7 dpi, all animals were euthanized and lung tissue was collected for virological and histological analyses. Although levels of gRNA and sgRNA were lower in lung lobes of remdesivir-treated animals, this difference was not statistically significant.

Histopathologic changes of mild interstitial pneumonia were detected in 5 out of 6 vehicle-treated animals, but not in any of the animals receiving subcutaneous remdesivir (Fig. 2A–C). Viral antigen could be detected in all animals regardless of treatment group (Fig. 2D). Together, our data indicate a reduction of respiratory signs, virus replication in the lower respiratory tract and a reduction in damage to the lungs with early initiation of subcutaneous remdesivir treatment.

One caveat of our study is that a direct comparison to our previous study on the efficacy of intravenous administration (Williamson et al., 2020) is impossible due to differences in the origin of rhesus macaques (Chinese-origin versus Indian-origin) that results in a difference in clinical signs, pulmonary infiltrates and histologic lung lesions. However, subcutaneous administration of remdesivir effectively prevented the development of lower respiratory tract disease, as did intravenous administration.

Recent clinical trial data showed a lack of improvement with remdesivir treatment in hospitalized patients (Ader et al., 2021). Although this may mean remdesivir treatment has limited effect in hospitalized patients, remdesivir treatment in non-hospitalized patients resulted in a significant reduction in hospitalizations (Gottlieb et al., 2021). Remdesivir is a direct-acting antiviral, and benefits of treatment are thus more likely to occur early during the infection when virus replication peaks, rather than during severe disease that is largely immune-driven. SARS-CoV-2 neutralizing monoclonal antibody therapies have shown great benefit when used to prevent rather than treat severe COVID-19 (reviewed in (Hurt and Wheatley, 2021)). Likewise, the development of new remdesivir formulations that are easier to administer in outpatient settings may result in an increased benefit of treatment. Since remdesivir is a broad-acting antiviral with efficacy against paramyxoviruses and filoviruses besides coronaviruses (Lo et al., 2017), the identification of alternative administration routes for remdesivir could have a much broader impact than on COVID-19 patients alone.

Data availability

Data included in this manuscript have been deposited in Figshare: https://figshare.com/articles/dataset/Subcutaneous_remdesivir_admi nistration_prevents_interstitial_pneumonia_in_rhesus_macaques_i noculated_with_SARS-CoV-2/16900057.

Declaration of competing interest

BNW, LP-P, BS, FF, MH, MS, EH, AO, JL, CMB, GS and EdW have no conflicts to declare, DSL, DB, RS, DPP, RLM and TC are employees of Gilead Sciences and own company stock.

Acknowledgements

We thank Tina Thomas, Dan Long, Rebecca Rosenke, Marissa Woods, Cathy Cordova, Carl Shaia and Vincent Munster for technical assistance; RMVB animal care staff for taking care of the animals, and Anita Mora for help with figure preparation. This study was supported by the Intramural Research Program of NIAID, NIH.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.antiviral.2022.105246.

References

Ader, F., Boussacumbert-Duchamp, M., Hites, M., Peiffer-Smadja, N., Poissy, J., Belhadi, D., Diallo, A., Le, M.P., Peytavin, G., Staib, T., Greil, R., Goedj, J., Paiva, J.A., Costagliola, D., Yazdanpanah, Y., Burdet, C., Mentre, F., DisCoVeRy Study, G., 2021. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect. Dis. In press.

Alexis, M.M., Silverman, E.A., Paredes Acomta, L.M., Ntt, C.T., Richterman, A., Marty, F.M., 2020. New perspectives on antiviral agents: remdesivir treatment for COVID-19. Antimicrob. Agents Chemother. 65.

Beigel, J.H., Tomasek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., Hohmann, E., Chu, H.Y., Luuetkemeyer, A., Klise, S., Lopez de Castilla, D., Finberg, R.W., Diergberg, K., Tapson, V., Hsieh, L., Patterson, T.P., Paredes, R., Sweeney, D.A., Short, W.B., Touloumi, G., Lye, D.C., Omaghari, N., Oh, M.D., Ruiz-Palacios, G.M., Benfield, T., Fattenheuer, G., Kortepeter, M.G., Atmar, R.L., Creeb, C.C., Lundgren, J., Babiker, A.G., Pett, S., Neaton, J.D., Burgess, T.H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayar, S., Lane, H.C., Members, A.-S., 2020. Remdesivir for the treatment of covid-19 - final report. N. Engl. J. Med. 383, 1813-1826.

Cox, R.M., Wolf, J.D., Lieber, C.M., Sournain, J., Lin, M.J., Babuis, D., DuPont, V., Chan, J., Barret, F.K., Lye, D., Kalla, R., Chun, K., Mackman, R.L., Ye, C., Cihlar, T., Martinez-Sobrido, L., Greninger, A.L., Billelo, J.P., Plemer, R.K., 2021. Oral produrg of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nat. Commun. 12, 6415.

Gottlieb, R.L., Vaca, C.E., Paredes, R., Mera, J., Webb, B.J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B.U., Brown, M., Hidalgo, A., Sachdeva, Y., Mittal, S., Oyiyemi, O., Skarbinski, J., Junkeja, K., Hyland, R.H., Osinusi, A., Chen, S., Camus, G., Abdelghany, M., Davies, S., Beherena-Renton, N., Duff, F., Marty, F.M., Katz, M.J., Ginde, A.A., Brown, S.M., Schiffer, J.T., Hill, J.A., Investigators, G.-U., 2021. Early remdesivir to prevent progression to severe covid-19 in outpatients. N. Engl. J. Med. In press.

Hurt, A.C., Wheatley, A.K., 2021. Neutralizing antibody therapeutics for COVID-19. Viruses 13.

Lo, M.K., Jordan, R., Arvey, A., Sudhamsu, J., Shirivastava-Ranjpan, P., Hotard, A.L., Flint, M., McMullan, L.K., Siegel, D., Clarke, M.O., Mackman, R.L., Hui, H.C., Perron, M., Ray, A.S., Cihlar, T., Nichol, S.T., Spiropoulou, C.F., 2017. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 7, 43395.

Munster, V.J., Feldmann, F., Williamson, B.N., van Doremalen, N., Perez-Perez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Braumbaugh, B., Avanzato, V., A., Rosenke, R., Hanley, P.W., Saturday, G., Scott, D., Fischer, E.R., de Wit, E., 2020. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 585, 268-272.

Warren, T.K., Jordan, R., Lo, M.K., Ray, A.S., Mackman, R.L., Sololova, V., Siegel, D., Perron, M., Bannister, R., Hui, H.C., Larson, N., Strickley, R., Wells, J., Stuthman, K.S., Van Tongeren, S.A., Garza, N.L., Donnelly, G., Shurtleff, A.C., Ketzerer, C.J., Gharabek, D., Zamani, R., Kenny, T., Eaton, B.P., Grimes, E., Welch, L.S., Gomba, L., Wilhelmsen, C.L., Nichols, D.K., Nuss, J.E., Nagle, E.R., Kugelman, J.R., Palacios, G., Doerffler, E., Neville, S., Carra, M.O., Zhang, L., Lev, W., Ross, B., Wang, Q., Chun, K., Wolfe, L., Babuis, D., Park, Y., Scott, D., Fischer, E.R., de Wit, E., 2020. SARS-CoV-2 neutralizing monoclonal antibody therapies have shown great benefit when used to prevent rather than treat severe COVID-19 (reviewed in (Hurt and Wheatley, 2021)). Likewise, the development of new remdesivir formulations that are easier to administer in outpatient settings may result in an increased benefit of treatment. Since remdesivir is a broad-acting antiviral with efficacy against paramyxoviruses and filoviruses besides coronaviruses (Lo et al., 2017), the identification of alternative administration routes for remdesivir could have a much broader impact than on COVID-19 patients alone.

Data availability

Data included in this manuscript have been deposited in Figshare: https://figshare.com/articles/dataset/Subcutaneous_remdesivir_admi nistration_prevents_interstitial_pneumonia_in_rhesus_macaques_i noculated_with_SARS-CoV-2/16900057.

Declaration of competing interest

BNW, LP-P, BS, FF, MH, MS, EH, AO, JL, CMB, GS and EdW have no conflicts to declare, DSL, DB, RS, DPP, RLM and TC are employees of Gilead Sciences and own company stock.

Acknowledgements

We thank Tina Thomas, Dan Long, Rebecca Rosenke, Marissa Woods, Kathy Cordova, Carl Shaia and Vincent Munster for technical assistance; RMVB animal care staff for taking care of the animals, and Anita Mora for help with figure preparation. This study was supported by the Intramural Research Program of NIAID, NIH.